Annals
Established in 1927 by the American College of Physicians
:
Advanced search
 
box Article
 arrow  Table of Contents                
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Tyring, S. K.
space
 arrow  PubMed                        
space

REPLY

Effects of Famciclovir in Acute Herpes Zoster

right arrow Stephen K. Tyring, MD, PhD

15 April 1996 | Volume 124 Issue 8 | Page 775


IN RESPONSE:

The investigators and the institutional review boards of the 36 participating centers in the United States, Canada, and Australia considered the study design to be both ethical and acceptable. Our first patient received study medication in November 1990, shortly after acyclovir had been approved for the short-term treatment of herpes zoster without documented effect on postherpetic neuralgia (April 1990). In contrast, as stated in our report, famciclovir significantly reduced the time to resolution of postherpetic neuralgia (a prospectively defined end point) in the overall sample, as well as in patients 50 years of age or older, who are at greatest risk for developing postherpetic neuralgia. Finally, as Dr. Tirelli acknowledges, we clearly stated the lack of benefit from famciclovir for patients younger than 50 years of age. We felt no need to further stress a result that was neither particularly surprising nor in conflict with existing thinking about treating herpes zoster in persons younger than 50 years of age.


Author and Article Information
space
up arrowTop
dotAuthor & Article Info

University of Texas Medical Branch; Galveston, TX 77555

About Letters
space

The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:

•Include no more than 300 words of text, three authors, and five references

•Type with double-spacing

•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.

Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.

Annals welcomes electronically submitted letters.





box Article
 arrow  Table of Contents                
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Tyring, S. K.
space
 arrow  PubMed                        
space


 Home | Current Issue | Past Issues | In the Clinic | ACP Journal Club | CME | Collections | Audio/Video | Mobile | Subscribe | Tools | Help | ACP Online